Jaguar Health, Inc.
JAGXOther · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | |
|---|---|---|---|---|---|---|
| Revenue | $11.5M | $11.7M | $9.8M | $12.0M | $4.3M | $9.4M |
| Operating income | −$45.9M | −$30.8M | −$34.3M | −$34.4M | −$40.7M | −$26.6M |
| Net income | −$53.6M | −$38.5M | −$41.3M | −$47.5M | −$52.6M | −$33.8M |
| Total assets | $38.3M | $53.4M | $50.8M | $47.5M | $53.3M | $42.8M |
| Total liabilities | $57.0M | $44.4M | $45.9M | $48.8M | $41.4M | $25.6M |
| Equity | −$18.7M | $6.5M | $4.9M | −$1.4M | $11.9M | $17.2M |
| EPS (diluted) | $-22.97 | $-130.69 | $-1.79 | $-36.18 | $-88.22 | $-3.00 |
| Shares out. | 2.3M | 294,534 | 23.1M | 1.3M | 596,154 | 12.9M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- −398.8%
- Net margin
- −465.4%
- Return on equity
- 286.7%
- Return on assets
- −139.8%
- Return on capital (ROCE)
- —
- Liabilities / assets
- 148.8%
- Debt / equity
- —
- Book value / share
- $-8.01
- Revenue growth (YoY)
- −1.5%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Altman Z″ (distress)
- -45.89distress
- Accruals / assets
- −78.0%clean
- Beneish M-Score
- -6.43normal
- Piotroski F-Score
- 2/9weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast. What these scores mean →
Signs
● 3 severe● 5 warning● 2 good- Negative shareholder equity
- Altman Z″ in the distress zone
- Filed a late-filing notice (Form NT) — missed an SEC deadline
- Operating losses (negative operating margin)
- Reported a net loss
- Revenue declined year-over-year
- High leverage (liabilities > 70% of assets)
- Negative operating cash flow
- Strong return on equity (>15%)
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Risk flags
late SEC filings- NT 10-Qmissed a reporting deadline ↗May 18, 2026
- NT 10-Kmissed a reporting deadline ↗Apr 1, 2026
- NT 10-Qmissed a reporting deadline ↗Aug 16, 2022
- NT 10-Qmissed a reporting deadline ↗Nov 15, 2021
- NT 10-Kmissed a reporting deadline ↗Mar 31, 2020
- NT 10-Qmissed a reporting deadline ↗May 15, 2019
A Form NT means the company notified the SEC it would file a periodic report late — often an accounting, audit or liquidity warning sign. Also search SEC enforcement actions for this company.
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Micek JohnDirector | Dec 11, 2025 | Grant | 7,377 | $0.00 |
| King Steven R.Officer — See Remarks | Dec 11, 2025 | Grant | 11,740 | $0.00 |
| Conte Lisa AOfficer — See Remarks | Dec 11, 2025 | Grant | 28,592 | $0.00 |
| Wolin Jonathan S.Officer — See Remarks | Dec 11, 2025 | Grant | 11,740 | $0.00 |
| Chaturvedi Pravin ROfficer — Chief Scientific Officer | Dec 11, 2025 | Grant | 11,740 | $0.00 |
| Bochnowski James JDirector | Dec 11, 2025 | Grant | 6,363 | $0.00 |
| Siegel Jonathan B.Director | Dec 11, 2025 | Grant | 7,377 | $0.00 |
| Jayasuriya AnulaDirector | Dec 11, 2025 | Grant | 5,870 | $0.00 |
| Lizak Carol R.Officer — Chief Financial Officer | Dec 11, 2025 | Grant | 11,740 | $0.00 |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 67,479 | 1.0 | -37.3% |
| Apr 30, 2026 | 107,543 | 5.5 | -82.1% |
| Apr 15, 2026 | 599,897 | 1.0 | +24.6% |
| Mar 31, 2026 | 481,255 | 1.5 | +10.8% |
| Mar 13, 2026 | 434,273 | 1.0 | +32.6% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Regulation FD disclosure · Other material eventMay 27, 2026
- Entered a material agreement · Other material eventMay 22, 2026
- Results of operationsMay 20, 2026
- Entered a material agreement · New financial obligation · Unregistered equity sale · Amended charter or bylawsMay 19, 2026
- Other material eventMay 7, 2026
- Other material eventMay 4, 2026
- Delisting / listing-standard noticeMay 4, 2026
- Delisting / listing-standard notice · Modified shareholder rights · Amended charter or bylaws · Regulation FD disclosureApr 27, 2026
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗Event-driven situations (1)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.